Tim C. Lai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tim C. Lai has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Cassidi C. McDaniel
Department of Health Outcomes Research and Policy, Harrison College of Pharmacy, Auburn University, Auburn, AL, USA
2 shared publications - Chiahung Chou
Department of Health Outcomes Research and Policy, Auburn University Harrison College of Pharmacy, Auburn, USA
2 shared publications Courtney P. McDonald
Specialty Pharmacy John B Amos Cancer Center Columbus Georgia USA
1 shared publicationDevan Rockwell
Family Medicine‐Clinical Services University of South Alabama Mobile Alabama USA
1 shared publicationFeng‐Hua Loh
Department of Social, Behavioral, and Administrative Sciences Touro College of Pharmacy New York City New York USA
1 shared publication- Heather P. Whitley
Department of Pharmacy Practice, Auburn University Harrison College of Pharmacy 2 , Auburn, AL
1 shared publication
Latest Publications
- 28 August 2025
- Published by American Diabetes Association in Clinical Diabetes
- Vol. 43 (5) , 670-680
Important Continuous Glucose Monitoring Attributes for Patients With Type 2 Diabetes
Although patient preferences are heterogeneous, the out-of-pocket cost and accuracy of continuous glucose monitoring (CGM) systems are the two most important attributes for patients with type 2 diabetes. Surprisingly, receiver screen information is not considered important when choosing a CGM system. Identifying important attributes could facilitate patient-provider communications in choosing a preferred CGM system and potentially increase adherence. Improving patient education on interpreting the information on the receiver screen could enhance the benefit of using CGM.
- 28 August 2025
- Published by American Diabetes Association in Clinical Diabetes
- Vol. 43 (5) , 670-680
Important Continuous Glucose Monitoring Attributes for Patients With Type 2 Diabetes
Although patient preferences are heterogeneous, the out-of-pocket cost and accuracy of continuous glucose monitoring (CGM) systems are the two most important attributes for patients with type 2 diabetes. Surprisingly, receiver screen information is not considered important when choosing a CGM system. Identifying important attributes could facilitate patient-provider communications in choosing a preferred CGM system and potentially increase adherence. Improving patient education on interpreting the information on the receiver screen could enhance the benefit of using CGM.
- Open Access
- 15 May 2023
- Published by Elsevier in Preventive Medicine Reports
- Vol. 34, 102247
HIV testing and risk behaviors associated with depression in the United States
- 15 May 2023
- Published by Elsevier in Preventive Medicine Reports
- Vol. 34, 102247
Open AccessHIV testing and risk behaviors associated with depression in the United States
- Open Access
- 13 April 2023
- Published by Wiley in Health Science Reports
- Vol. 6 (4) , e1193
Reproducibility of the medical cost estimation from the Medicare Current Beneficiary Survey: Comparing claims and survey
Background: The Medicare Current Beneficiary Survey (MCBS) limited‐access data provides the unique opportunity to utilize administrative claims and adjusted survey data to investigate trends in utilization and medical expenditure across time. The adjusted survey data is a synthesized, matched version of the original survey data and claims. Researchers may choose adjusted survey data or original claims for cost evaluations according to their research purpose. However, limited research has examined methodological issues when estimating medical cost using different MCBS data sources.Objective: The study objective was to examine the reproducibility of individual‐level medical cost using both MCBS data sources: adjusted survey and claims data.Methods: This serial cross‐sectional study design analyzed 2006–2012 MCBS data. The sample included noninstitutionalized older Medicare beneficiaries (≥65 years old), with a cancer diagnosis and annually enrolled in Medicare Parts A, B, and D. The population was stratified by diabetes diagnosis. The primary outcome was annual medical cost. We investigated the discrepancies of medical cost estimated from the adjusted survey and original claims data. The agreement between cost estimates from the two sources in each year was determined using the Wilcoxon signed‐rank test.Results: A total of 4918 eligible Medicare beneficiaries were included in this study, and 26% of beneficiaries also had diabetes (N = 1275). Significant disagreements in cost estimates between adjusted survey and claims data were present regardless of disease complexity (with or without diabetes). Significant disagreements in medical cost estimates were present in most years, except in 2010 (p = 0.467) and 2011 (p = 0.098), for beneficiaries with cancer and diabetes (p < 0.001 for all). Significant disagreements in medical cost estimates were present in all years for beneficiaries with cancer without diabetes (p < 0.001 for all).Conclusions: Based on discrepant cost estimates across data sources, researchers using MCBS to estimate costs should be cautious when using claims or adjusted survey data alone.
- 13 April 2023
- Published by Wiley in Health Science Reports
- Vol. 6 (4) , e1193
Open AccessReproducibility of the medical cost estimation from the Medicare Current Beneficiary Survey: Comparing claims and survey
Background: The Medicare Current Beneficiary Survey (MCBS) limited‐access data provides the unique opportunity to utilize administrative claims and adjusted survey data to investigate trends in utilization and medical expenditure across time. The adjusted survey data is a synthesized, matched version of the original survey data and claims. Researchers may choose adjusted survey data or original claims for cost evaluations according to their research purpose. However, limited research has examined methodological issues when estimating medical cost using different MCBS data sources.Objective: The study objective was to examine the reproducibility of individual‐level medical cost using both MCBS data sources: adjusted survey and claims data.Methods: This serial cross‐sectional study design analyzed 2006–2012 MCBS data. The sample included noninstitutionalized older Medicare beneficiaries (≥65 years old), with a cancer diagnosis and annually enrolled in Medicare Parts A, B, and D. The population was stratified by diabetes diagnosis. The primary outcome was annual medical cost. We investigated the discrepancies of medical cost estimated from the adjusted survey and original claims data. The agreement between cost estimates from the two sources in each year was determined using the Wilcoxon signed‐rank test.Results: A total of 4918 eligible Medicare beneficiaries were included in this study, and 26% of beneficiaries also had diabetes (N = 1275). Significant disagreements in cost estimates between adjusted survey and claims data were present regardless of disease complexity (with or without diabetes). Significant disagreements in medical cost estimates were present in most years, except in 2010 (p = 0.467) and 2011 (p = 0.098), for beneficiaries with cancer and diabetes (p < 0.001 for all). Significant disagreements in medical cost estimates were present in all years for beneficiaries with cancer without diabetes (p < 0.001 for all).Conclusions: Based on discrepant cost estimates across data sources, researchers using MCBS to estimate costs should be cautious when using claims or adjusted survey data alone.